Sharada Weir1,2, Mihail Samnaliev1,3, Tzu-Chun Kuo1, Travis S Tierney4, Silke Walleser Autiero5, Rod S Taylor6, Anette Schrag7. 1. PHMR, LLC, London, UK. 2. Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. 3. Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts, USA. 4. Brain Institute at Nicklaus Children's Hospital, University of Miami Miller School of Medicine, Miami, Florida, USA. 5. Medtronic International Trading Sàrl, Tolochenaz, Switzerland. 6. Institute of Health Research, University of Exeter Medical School, Exeter, UK. 7. UCL Institute of Neurology, London, UK.
Abstract
BACKGROUND: There is currently no robust long-term data on costs of treating patients with Parkinson's disease. The objective of this study was to report levels of health care utilization and associated costs in the 10 years after diagnosis among PD patients in the United Kingdom. METHODS: We undertook a retrospective population-based cohort study using linked data from the UK Clinical Practice Research Datalink and Hospital Episode Statistics databases. Total health care costs of PD patients were compared with those of a control group of patients without PD selected using 1:1 propensity score matching based on age, sex, and comorbidity. RESULTS: Between 1994 and 2013, 7271 PD patients who met study inclusion criteria were identified in linked Clinical Practice Research Datalink-Hospital Episode Statistics; 7060 were matched with controls. The mean annual health care cost difference (at 2013 costs) between PD patients and controls was £2471 (US$3716) per patient in the first year postdiagnosis (P < 0.001), increasing to £4004 (US$6021) per patient (P < 0.001) 10 years following diagnosis because of higher levels of use across all categories of health care utilization. Costs in patients with markers of advanced PD (ie, presence of levodopa-equivalent daily dose > 1100 mg, dyskinesias, falls, dementia, psychosis, hospital admission primarily due to PD, or nursing home placement) were on average higher by £1069 (US$1608) per patient than those with PD without these markers. CONCLUSIONS: This study provides comprehensive estimates of health care costs in PD patients based on routinely collected data. Health care costs attributable to PD increase in the year following diagnosis and are higher for patients with indicators of advanced disease.
BACKGROUND: There is currently no robust long-term data on costs of treating patients with Parkinson's disease. The objective of this study was to report levels of health care utilization and associated costs in the 10 years after diagnosis among PDpatients in the United Kingdom. METHODS: We undertook a retrospective population-based cohort study using linked data from the UK Clinical Practice Research Datalink and Hospital Episode Statistics databases. Total health care costs of PDpatients were compared with those of a control group of patients without PD selected using 1:1 propensity score matching based on age, sex, and comorbidity. RESULTS: Between 1994 and 2013, 7271 PDpatients who met study inclusion criteria were identified in linked Clinical Practice Research Datalink-Hospital Episode Statistics; 7060 were matched with controls. The mean annual health care cost difference (at 2013 costs) between PDpatients and controls was £2471 (US$3716) per patient in the first year postdiagnosis (P < 0.001), increasing to £4004 (US$6021) per patient (P < 0.001) 10 years following diagnosis because of higher levels of use across all categories of health care utilization. Costs in patients with markers of advanced PD (ie, presence of levodopa-equivalent daily dose > 1100 mg, dyskinesias, falls, dementia, psychosis, hospital admission primarily due to PD, or nursing home placement) were on average higher by £1069 (US$1608) per patient than those with PD without these markers. CONCLUSIONS: This study provides comprehensive estimates of health care costs in PDpatients based on routinely collected data. Health care costs attributable to PD increase in the year following diagnosis and are higher for patients with indicators of advanced disease.
Authors: Yiqiao Xin; Ann Ashburn; Ruth M Pickering; Kim Chivers Seymour; Sophia Hulbert; Carolyn Fitton; Dorit Kunkel; Ioana Marian; Helen C Roberts; Sarah E Lamb; Victoria A Goodwin; Lynn Rochester; Emma McIntosh Journal: BMC Neurol Date: 2020-08-11 Impact factor: 2.474